News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SynAgile Announces Closing Of $10.4 Million Financing



8/24/2017 7:43:37 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

WILSON, Wyoming, Aug. 24, 2017 /PRNewswire/ -- SynAgile Corporation (www.SynAgile.com), a privately held pharmaceutical company that develops and commercializes drug delivery systems using its proprietary OraFuse technology platform, today announced the closing of a $10.4 million round of equity investment. The round was led by affiliates of TAMCAP LLC. The proceeds will be used to conduct the first-in-human, Phase 2 clinical trial of SynAgile's DopaFuse delivery system. The DopaFuse delivery system is the first non-invasive, continuous, levodopa-carbidopa delivery system for the treatment of motor fluctuations associated with Parkinson's disease.

About SynAgile

SynAgile is a biopharmaceutical company focused on developing and commercializing transformative therapeutics using its proprietary OraFuse noninvasive, continuous, oral dosing technology, with an initial focus on treating debilitating motor complications in patients with Parkinson's disease using its DopaFuse levodopa-carbidopa delivery system.

OraFuse and DopaFuse are trademarks of SynAgile Corporation.

Contact
SynAgile Corporation
Ephraim Heller, (510) 788-4435
eheller@synagile.com

 

View original content:http://www.prnewswire.com/news-releases/synagile-corporation-announces-closing-of-104m-financing-300508096.html

SOURCE SynAgile Corporation


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES